Koharu Loulou Chayama1,2, Jenna Valleriani1,2, Cara Ng1, Rebecca Haines-Saah3, Rielle Capler1,2, M-J Milloy1,2, Will Small1,4, Ryan McNeil1,5,6. 1. British Columbia Centre on Substance Use, Vancouver, Canada. 2. Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. 3. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada. 4. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 5. Department of Internal Medicine, Yale School of Medicine, New Haven, USA. 6. Program in Addiction Medicine, Yale School of Medicine, New Haven, USA.
Abstract
INTRODUCTION: People living with HIV who use drugs commonly experience chronic pain and often use illicit opioids to manage pain. Recent research suggests people living with HIV use cannabis for pain relief, including as an adjunct to opioids. This underscores the need to better understand how people living with HIV who use drugs use cannabis for pain management, particularly as cannabis markets are undergoing changes due to cannabis legalisation. METHODS: From September 2018 to April 2019, we conducted in-depth interviews with 25 people living with HIV who use drugs in Vancouver, Canada to examine experiences using cannabis to manage pain. Interviews were audio-recorded, transcribed and coded. Themes were identified using inductive and deductive approaches. RESULTS: Most participants reported that using cannabis for pain management helped improve daily functioning. Some participants turned to cannabis as a supplement or periodic alternative to prescription and illicit drugs (e.g. benzodiazepines, opioids) used to manage pain and related symptoms. Nonetheless, participants' access to legal cannabis was limited and most continued to obtain cannabis from illicit sources, which provided access to cannabis that was free or deemed to be affordable. DISCUSSION AND CONCLUSIONS: Cannabis use may lead to reduced use of prescription and illicit drugs for pain management among some people living with HIV who use drugs. Our findings add to growing calls for additional research on the role of cannabis in pain management and harm reduction, and suggest the need for concrete efforts to ensure equitable access to cannabis.
INTRODUCTION: People living with HIV who use drugs commonly experience chronic pain and often use illicit opioids to manage pain. Recent research suggests people living with HIV use cannabis for pain relief, including as an adjunct to opioids. This underscores the need to better understand how people living with HIV who use drugs use cannabis for pain management, particularly as cannabis markets are undergoing changes due to cannabis legalisation. METHODS: From September 2018 to April 2019, we conducted in-depth interviews with 25 people living with HIV who use drugs in Vancouver, Canada to examine experiences using cannabis to manage pain. Interviews were audio-recorded, transcribed and coded. Themes were identified using inductive and deductive approaches. RESULTS: Most participants reported that using cannabis for pain management helped improve daily functioning. Some participants turned to cannabis as a supplement or periodic alternative to prescription and illicit drugs (e.g. benzodiazepines, opioids) used to manage pain and related symptoms. Nonetheless, participants' access to legal cannabis was limited and most continued to obtain cannabis from illicit sources, which provided access to cannabis that was free or deemed to be affordable. DISCUSSION AND CONCLUSIONS: Cannabis use may lead to reduced use of prescription and illicit drugs for pain management among some people living with HIV who use drugs. Our findings add to growing calls for additional research on the role of cannabis in pain management and harm reduction, and suggest the need for concrete efforts to ensure equitable access to cannabis.
Authors: Gregory E Harris; Lise Dupuis; Gerald J Mugford; Lynn Johnston; David Haase; Ginny Page; Heather Haldane; Nicholas Harris; William K Midodzi; Gordon Dow Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471
Authors: Fiona Charlson; Louisa Degenhardt; Jennifer McLaren; Wayne Hall; Michael Lynskey Journal: Pharmacoepidemiol Drug Saf Date: 2009-02 Impact factor: 2.890
Authors: Stephanie Lake; Zach Walsh; Thomas Kerr; Ziva D Cooper; Jane Buxton; Evan Wood; Mark A Ware; M J Milloy Journal: PLoS Med Date: 2019-11-19 Impact factor: 11.069
Authors: Tara Gomes; David N Juurlink; Tony Antoniou; Muhammad M Mamdani; J Michael Paterson; Wim van den Brink Journal: PLoS Med Date: 2017-10-03 Impact factor: 11.069